Menu
Recruiting NCT06148883

Management of Patients With New Left Bundle Branch Block After Transcatheter Aortic Valve Implantation

No phase Interventional Left Bundle-Branch Block

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Transcatheter Aortic Valve Implantation.
Who it may be relevant to
Registry conditions: Left Bundle-Branch Block. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Comparison of Early Ambulatory Monitoring Strategy Versus Electrophysiological Study Approach in the Management of Patients With New Left Bundle Branch Block After Transcatheter Aortic Valve Implantation

Overview

The purpose of this study is to show that Electrocardiogram Ambulatory Monitoring-guided strategy is superior to ElectroPhysiological Study on the rate of alive patients with an appropriate Pacemaker implantation/non-implantation, at 12 months after randomization, in patients with New Onset Persistent Left Bundle Branch Block after Transcatheter Aortic Valve Implantation.

Detailed description

This is a prospective, multicentric, randomized in parallel group, controlled, open labelled clinical study.

* After Transcatheter Aortic Valve Implantation, all consecutive patients presenting with new onset Left Bundle Branch Block will undergo in-hospital telemetry. In case of persistence (at least 48 hours) of a stable (i.e., no change in the last 24 hours) Left Bundle Branch Block \> 150 ms, and in the absence of high grade Aortic Valve block or persistent prolonged PR interval \> 240 ms, patients will be eligible for the study * After written consent will be obtained, included patients will be randomized into two groups according to a 1:1 ratio:

* Electrocardiogram Ambulatory Monitoring for 1 month and immediate discharge. In this group, Pacemaker implantation will be decided, after discharge, on documented Electrocardiogram abnormalities obtained from the 1 month Electrocardiogram Ambulatory Monitoring. Any other clinically relevant therapeutic decision based on Electrocardiogram Ambulatory Monitoring will be taken or * ElectroPhysiological Study for infra-hisian conduction evaluation. Pacemaker implantation will be decided, before discharge, in case of prolonged His-Ventricular interval ≥ 70 ms * Patients in both groups will be followed until the end of the first year after randomization. Follow-up visits will be scheduled in person at 1 and 12 months, and through telemedicine at 3 and 6 months. Appropriateness of Pacemaker implantation/non-implantation will be evaluated at each follow-up time * In case of any occurrence of syncope, patients will be evaluated in person, by the principal investigator of each centre, to evaluate and manage the syncope as recommended by the European Society of Cardiology guidelines.

Patients will be followed-up according to current practice.

Interventions

  • Procedure Transcatheter Aortic Valve Implantation
    Transcatheter Aortic Valve Implantation is the implantation of a biological aortic valve percutaneously

Primary outcome measures

  • Alive status with appropriate Pacemaker implantation/non-implantation [Time frame: 12 months]

Eligibility criteria

Inclusion criteria

Patients who are 18 years or older and undergo Transcatheter Aortic Valve Implantation :

  • Presenting with New Onset Persistent Left Bundle Branch Block, defined as a new Left Bundle Branch Block >150 ms that persists at least two days after Transcatheter Aortic Valve Implantation and is stable
  • With an anticipated life expectancy >1 year
  • Who consent to participate to the study

Exclusion criteria

  • During in-hospital Electrocardiogram monitoring period, immediately after Transcatheter Aortic Valve Implantation and before inclusion:
  • Documented high grade Atrio Ventricular block (Atrio Ventricular block of a degree higher than Mobitz I)
  • Persistent PR interval prolongation > 240 ms
  • Occurrence of syncope or sudden cardiac death,
  • Identification of any indisputable criteria for Pacemaker implantation
  • Definitive Pacemaker implantation
  • Prior Pacemaker or Implantable Cardiac defibrillator
  • Indication for Cardiac Resynchronization Therapy or Implantable cardiac defibrillator
  • Pre-existing Left Bundle Branch Block or Right Bundle Branch Block
  • Pre-existing PR interval prolongation > 240 ms
  • Severe or moderate dementia, evaluated before Transcatheter Aortic Valve Implantation, defined as a Mini Mental State Examination < 15
  • Pregnancy or breastfeeding patient
  • No affiliation to a social security scheme
  • Adult under legal protection (trusteeship, guardianship).

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

France · 1 center
  • Hôpital de la Timone - APHM — Marseille

Identifiers

NCT: NCT06148883 · 2022-A02699-34

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗